For the quarter ending 2025-09-30, BMRN made $776,133K in revenue. -$30,744K in net income. Net profit margin of -3.96%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 776,133 | 825,410 | 745,145 | 747,313 |
| Cost of sales | 140,085 | 150,090 | 151,558 | 136,139 |
| Research and development | 409,478 | 161,308 | 158,731 | 173,509 |
| Selling, general and administrative | 268,415 | 232,279 | 206,116 | 266,607 |
| Intangible asset amortization | 4,847 | 4,846 | 4,847 | 9,651 |
| Gain on sale of nonfinancial assets | 0 | 0 | 0 | 0 |
| Total operating expenses | 822,825 | 548,523 | 521,252 | 585,906 |
| Income (loss) from operations | -46,692 | 276,887 | 223,893 | 161,407 |
| Interest income | 17,854 | 18,827 | 19,013 | 17,680 |
| Interest expense | 2,579 | 2,679 | 2,863 | 3,062 |
| Other income, net | 5,093 | 4,833 | -1,954 | -6,871 |
| Income (loss) before income taxes | -26,324 | 297,868 | 238,089 | 169,639 |
| Provision for income taxes | 4,420 | 57,336 | 52,403 | 44,696 |
| Net income (loss) | -30,744 | 240,532 | 185,686 | 124,943 |
| Earnings (loss) per share, basic (in dollars per share) | -0.16 | 1.25 | 0.97 | 0.66 |
| Earnings (loss) per share, diluted (in dollars per share) | -0.16 | 1.23 | 0.95 | 0.65 |
| Weighted average common shares outstanding, basic (in shares) | 192,032,000 | 191,907,000 | 190,967,000 | -379,382,000 |
| Weighted average common shares outstanding, diluted (in shares) | 192,032,000 | 197,091,000 | 196,474,000 | -400,206,000 |
BIOMARIN PHARMACEUTICAL INC (BMRN)
BIOMARIN PHARMACEUTICAL INC (BMRN)